Publicaciones en colaboración con investigadores/as de Stony Brook University (16)

2024

  1. Prospective Cohort Study to Compare Long-Term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a–b; ≤20 mm) NSCLC Treated by Stereotactic Body Radiation Therapy and Surgery

    Journal of Thoracic Oncology, Vol. 19, Núm. 3, pp. 476-490

2022

  1. Role of EXO1 nuclease activity in genome maintenance, the immune response and tumor suppression in Exo1D173Amice

    Nucleic Acids Research, Vol. 50, Núm. 14, pp. 8093-8106

2021

  1. Digital acoustic surveillance for early detection of respiratory disease outbreaks in Spain: A protocol for an observational study

    BMJ Open, Vol. 11, Núm. 7

  2. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

    Future Oncology, Vol. 17, Núm. 11, pp. 1295-1310

  3. Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study

    International Immunopharmacology, Vol. 90

  4. Pharoh lncrna regulates myc translation in hepatocellular carcinoma via sequestering tiar

    eLife, Vol. 10

  5. The association between self-perceived walking pace with the incidence of hypertension: the 'Seguimiento Universidad de Navarra' cohort

    Journal of hypertension, Vol. 39, Núm. 6, pp. 1188-1194

2020

  1. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

    The Lancet Haematology, Vol. 7, Núm. 7, pp. e511-e522

2019

  1. Author Correction: ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development (Nature Immunology, (2019), 20, 11, (1409-1413), 10.1038/s41590-019-0503-1)

    Nature Immunology

  2. Identification of resistance pathways specific to malignancy using organoid models of pancreatic cancer

    Clinical Cancer Research, Vol. 25, Núm. 22, pp. 6742-6755

  3. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas

    Blood, Vol. 133, Núm. 22, pp. 2401-2412

  4. ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

    Nature Immunology

2015

  1. Organoid models of human and mouse ductal pancreatic cancer

    Cell, Vol. 160, Núm. 1-2, pp. 324-338

2014

  1. Consensus guidelines for the detection of immunogenic cell death

    OncoImmunology, Vol. 3, Núm. 9

2012

  1. IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions

    Blood, Vol. 120, Núm. 24, pp. 4802-4811

2007

  1. Computed tomographic screening for lung cancer: Individualising the benefit of the screening

    European Respiratory Journal, Vol. 30, Núm. 5, pp. 843-847